Forum uniquely brings together leading family offices, their foundations and sovereign wealth fund representatives seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences.
Seattle WA (PRWEB) October 12, 2015
NeuMedics Inc., is a specialty biopharmaceutical company focused on identifying and developing novel therapeutics for the treatment of retinal diseases that can safely and chronically be administered as an eye drop, announced today it has been selected to present at the Cavendish Global Health Impact Forum co-hosted by The Cleveland Clinic and taking place October 25th to October 28th at The Cleveland Clinic, Cleveland, Ohio. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the Forum showcases presentations and panel discussions by leading family offices, accomplished foundations, research institutions, and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. A unique gathering of family offices, Cavendish Impact Forums are hosted by leading institutions around the world and take place three times each year. The next Forum is being co-hosted by The Cleveland Clinic and Cleveland Clinic Innovations.
Michael Moffat, Cavendish co-founder and Chief Executive Officer explains, “The theme of our Cleveland Clinic hosted Forum is a ‘Celebration of Philanthropy, Impact Investing and Innovation that is Changing the World.’ With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of NeuMedics Inc. research and scientific insights into novel therapeutics that treat ophthalmic complications of Diabetes positions them to make a major contribution to all diabetics who are at risk of losing their vision."
“We are honored to be selected to present at this unique event, and it is further recognition of our innovative approach to treating –and possibly preventing blindness- in the significant global population of diabetics who have no little or no access to treatment.” said Iain Duncan, CEO NeuMedics Inc. “We welcome the chance to interact with many of world’s most accomplished scientists, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world.”
Cavendish Global consists of over 200 leading family offices and foundations from around the world with combined assets of over $260 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world.
NeuMedics is a specialty biopharmaceutical company focused on improving patients' lives by identifying and developing, novel therapeutics for the treatment of retinal diseases that can be safely and chronically administered as an eye drop. NeuMedics lead compound NM108 is a patented highly lipophilic small molecule that targets the upstream inflammatory mediators that contribute to VEGF leakage and has the potential to significantly reduce the need for intravitreal injections. For more information on NeuMedics, Inc. visit our website at http://www.NeuMedics.com
Media Contact : Iain W Duncan 206 352 9668
For the original version on PRWeb visit: http://www.prweb.com/releases/2015/10/prweb13014577.htm